Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency
Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 18

Showing 18 citing articles:

An Overview of Nanoparticle-Based Delivery Platforms for mRNA Vaccines for Treating Cancer
Lin Yang, Xuehua Chen, Ke Wang, et al.
Vaccines (2024) Vol. 12, Iss. 7, pp. 727-727
Open Access | Times Cited: 14
Harnessing T-Cells for Enhanced Vaccine Development against Viral Infections
Zhen Zhuang, Jianfen Zhuo, Yaochang Yuan, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 478-478
Open Access | Times Cited: 4
Viral T-cell epitopes – Identification, characterization and clinical application
Sarah M. Schroeder, Annika Nelde, Juliane S. Walz
Seminars in Immunology (2023) Vol. 66, pp. 101725-101725
Closed Access | Times Cited: 10
SARS-CoV-2 infection establishes a stable and age-independent CD8+ T cell response against a dominant nucleocapsid epitope using restricted T cell receptors
Cecily Choy, Joseph Chen, Jiangyuan Li, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Pan‐Variant SARS‐CoV‐2 Vaccines Induce Protective Immunity by Targeting Conserved Epitopes
Masaud Shah, Sung Ung Moon, Ji‐Yon Shin, et al.
Advanced Science (2025)
Open Access
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
Christopher Hackenbruch, Jens Bauer, Jonas S. Heitmann, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 3
Mapping the immunopeptidome of seven SARS-CoV-2 antigens across common HLA haplotypes
Asolina Braun, Louise C. Rowntree, Ziyi Huang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 3
The coevolution of Covid-19 and host immunity
Azizul Haque, Anudeep B. Pant
Exploration of Medicine (2024), pp. 167-184
Open Access | Times Cited: 2
Safety and Immunogenicity Study of a Bivalent Vaccine for Combined Prophylaxis of COVID-19 and Influenza in Non-Human Primates
Ekaterina Stepanova, Irina Isakova-Sivak, Victoria Matyushenko, et al.
Vaccines (2024) Vol. 12, Iss. 10, pp. 1099-1099
Open Access | Times Cited: 2
The impact of COVID-19 on cancer patients
Demi Wekking, Thilini H. Senevirathne, Josie Pearce, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 75, pp. 110-118
Closed Access | Times Cited: 6
A Mixture of T-Cell Epitope Peptides Derived from Human Respiratory Syncytial Virus F Protein Conferred Protection in DR1-TCR Tg Mice
Hong Guo, Yang Song, Hai Li, et al.
Vaccines (2024) Vol. 12, Iss. 1, pp. 77-77
Open Access | Times Cited: 1
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens
Alexander Englisch, Clara Hayn, Susanne Jung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
T Cell Peptide Prediction, Immune Response, and Host–Pathogen Relationship in Vaccinated and Recovered from Mild COVID-19 Subjects
Iole Macchia, Valentina La Sorsa, Alessandra Ciervo, et al.
Biomolecules (2024) Vol. 14, Iss. 10, pp. 1217-1217
Open Access | Times Cited: 1
Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines
Kevin A. Kovalchik, David Hamelin, Peter Kubiniok, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
An Overview of Nanoparticle-Based Delivery Platforms for Vaccines
Lin Yang, Xuehua Chen, Ke Wang, et al.
(2024)
Open Access
Coronavirus spike protein-based vaccines. Vaccine delivery systems
Akmal M. Asrorov, Mirzakamol S. Ayubov, Bin Tu, et al.
Medicine in Drug Discovery (2024), pp. 100198-100198
Open Access
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients
Susanne Jung, Annika Nelde, Yacine Maringer, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients
Jonas S. Heitmann, Susanne Jung, Marcel Wacker, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1

Scroll to top